What's happening
This bill requires insurance to fully cover FDA-approved or authorized COVID-19 antiviral drugs, capping cost-sharing and prioritizing free or reduced-cost programs.
Why it matters
Ensures financial protection for patients. by prohibiting insurance plans from applying deductibles or coinsurance to FDA-approved or authorized COVID-19 antiviral drugs, reducing out-of-pocket expenses for those needing treatment.
Guarantees access to the latest COVID-19 treatments. by mandating insurance coverage for all antiviral therapeutics that have received FDA approval or emergency use authorization, regardless of when they become available.
Coordinates with existing free/reduced-cost programs. by requiring patients to use manufacturer or government assistance programs first (if eligible), which helps control overall healthcare costs and preserves insurance resources for those without other options.
Expands coverage across all major health insurance types. (individual, group, blanket, and public plans like Medicaid), meaning the policy applies broadly and benefits a wide spectrum of New Yorkers, including vulnerable populations.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Patients with prescription drug coverage
The bill would require covered policies to cover prescribed FDA-approved or emergency-authorized COVID-19 antivirals without annual deductibles or coinsurance.
Health insurers
Insurers subject to the bill would have to provide this coverage but could require eligible patients able to obtain free or reduced-cost drugs through manufacturer or government programs to use those programs first.
Medicaid enrollees
The bill would add prescribed COVID-19 antivirals to Medicaid benefits at no cost, subject to the same provision allowing prior use of manufacturer or government assistance programs.
Headline styles
Cap COVID Drug Costs
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Delivered to assembly
- Passed senateVote 59–0
- Ordered to third reading cal.1501
- Committee discharged and committed to rules
- Print number 8367b
- Amend and recommit to insurance
- Print number 8367a
- Amend (t) and recommit to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cap COVID Drug Copays
In Assembly Committee · Insurance · Sponsor David Weprin
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8367--B
IN SENATE
January 23, 2024
Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 39 to read as follows:
(39) (A) Every policy that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.
(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.
§ 2. Subsection (k) of section 3221 of the insurance law is amended by adding a new paragraph 23 to read as follows:
(23) (A) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.
(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14144-04-4
required to use such program before using coverage required pursuant to this paragraph.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (vv) to read as follows:
(vv) (1) Every contract issued by a medical expense indemnity corporation, a hospital service corporation, or a health service corporation that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.
(2) Coverage under this subsection shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this subsection.
§ 4. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (nn) to read as follows:
(nn) (i) antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.
(ii) coverage under this paragraph shall be provided at no cost to the insured, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.
§ 5. This act shall take effect on the first day of January next succeeding the date on which it shall have become a law and shall apply to all policies and contracts issued, renewed, modified, altered, or amended on or after such date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics
Summary of provisions
Section one adds a new paragraph to section 3216 of the insurance law requiring individual insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.
Section two adds a new paragraph to section 3221 of the insurance law requiring group insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.
Section three adds a new paragraph to section 4303 of the insurance law requiring hospital service corporations or health service corporations insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.
Section four adds a new paragraph to section 365-a of the social services law Medicaid in New York State to provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.
Justification
Oral antiviral therapeutics can save the life of someone with COVID-19, having been shown to reduce the rate of serious illness and death from COVID by as much as 89 percent. Yet a 2023 study of by the National Institutes of Health found that only 9.7 percent of 1.3 million high- risk patients eligible for an oral antiviral prescription had actually received it (Hansen et al). These numbers can vary by demographic group, with a December 2023 study by researchers at the City University of New York finding that eligible Black and low-income patients take these medications at even lower rates (Shen et al).
Many oral antiviral therapeutics have shifted into the commercial market for distribution, at times costing more than $1,300 for a single prescription. Though federal and private cost assistance programs prom- ise to offset or eliminate the cost of a COVID-19 antiviral prescription through 2024, many insured New Yorkers could still face out-of-pocket costs that pose a barrier to uptake.
To ensure cost does not prohibit any New Yorker from taking life-saving medication to treat COVID-19, this bill would require private insurers and Medicaid to cover the full cost of COVID-19 oral antiviral therapeu- tics for eligible New Yorkers with a prescription.
Legislative history
New bill.
Fiscal implications
None to the state.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.